Atypical Parkinsonism

In a patient with progressive parkinsonism, initiate an atypical-parkinsonism evaluation when motor impairment is levodopa-poorly responsive or when early gait instability, falls, dysautonomia, cerebellar signs, prominent cognitive-behavioral change, eye-movement abnormalities, or cortical deficits accompany parkinsonism.PubMed+2PubMedThe Differential Diagnosis and Treatment of Atypical ParkinsonismPubMedThe Spectrum of Cognitive Impairment in Atypical Parkinsonism Syndromes: A Comprehensive Review of Current Understanding and ResearchPubMedDiagnostic Approach to Atypical Parkinsonian Syndromes - PMC The principal syndromic branches are multiple system atrophy (MSA), progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and dementia with Lewy bodies (DLB).PubMed+2PubMedThe Differential Diagnosis and Treatment of Atypical ParkinsonismPubMedAtypical parkinsonian syndromes: a general neurologist’s perspectivePubMedDiagnostic Approach to Atypical Parkinsonian Syndromes - PMC

Do not equate a clinical syndrome with a neuropathologic diagnosis. PSP and corticobasal degeneration are primary tauopathies, but the classic clinical corticobasal syndrome does not reliably establish corticobasal degeneration during life; use “CBS” for the clinical phenotype and reserve “CBD” for pathologically confirmed disease when possible.PubMed+2PubMedAtypical parkinsonian syndromes: a general neurologist’s perspectivePubMedProgressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkersPubMedBest Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care Likewise, clinical classification in specialized centers is useful but remains imperfect relative to neuropathology.PubMedPubMedThe Differential Diagnosis and Treatment of Atypical Parkinsonism

Escalate urgently when falls, dysphagia, aspiration risk, severe orthostatic symptoms, urinary retention, delirium, or caregiver inability to maintain safety becomes apparent. These complications change near-term management even when syndromic classification remains provisional; reassess medications for benefit and toxicity at each visit.PubMedPubMedBest Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care

Obtain brain MRI when atypical features are present, because structural imaging contributes to syndrome-based classification and helps evaluate alternative structural explanations for progressive parkinsonism.PubMed+1PubMedThe Differential Diagnosis and Treatment of Atypical ParkinsonismPubMedDiagnostic Approach to Atypical Parkinsonian Syndromes - PMC Interpret MRI alongside the evolving neurologic phenotype rather than as a stand-alone diagnosis, since clinical and imaging-based classification is not perfectly concordant with neuropathology.PubMedPubMedThe Differential Diagnosis and Treatment of Atypical Parkinsonism

In suspected MSA, separate neurogenic autonomic failure from common competing causes of orthostatic symptoms and evaluate the broader phenotype for parkinsonism, cerebellar ataxia, and corticospinal involvement.PubMedPubMedA Guide for the Differential Diagnosis of Multiple System ... A diagnostic error matters because MSA has a broad differential that includes nondegenerative disorders, some of which require different or potentially treatable interventions.PubMedPubMedA Guide for the Differential Diagnosis of Multiple System ...

Use targeted genetic evaluation when age at onset, family history, phenotype, or imaging suggests an inherited mimic. Genetic conditions can present with PSP-, CBS-, or MSA-like syndromes, and hereditary diffuse leukoencephalopathy with spheroids associated with CSF1R mutations is one reported example of a parkinsonian mimic.PubMedPubMedAtypical parkinsonian syndromes: a general neurologist’s perspective

Alpha-synuclein seeding amplification assays in CSF, skin, and potentially blood are emerging biologic tools for synucleinopathies, but they require careful validation before they can replace expert clinical assessment or determine an individual patient’s diagnosis.NatureNatureRevisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases | npj Parkinson's Disease Do not delay safety-directed interventions while awaiting biomarker development or research-based testing.

Current treatment for atypical parkinsonian syndromes is symptomatic.PubMed+1PubMedThe Differential Diagnosis and Treatment of Atypical ParkinsonismPubMedAvailable and future treatments for atypical parkinsonism. A ... A levodopa trial may be clinically reasonable when parkinsonism is disabling, but poor levodopa responsiveness is common across atypical parkinsonism and should prompt a shift toward function-directed interventions rather than repeated escalation of ineffective dopaminergic therapy.PubMed+2PubMedThe Differential Diagnosis and Treatment of Atypical ParkinsonismPubMedThe Spectrum of Cognitive Impairment in Atypical Parkinsonism Syndromes: A Comprehensive Review of Current Understanding and ResearchPubMedProgressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkers At every visit, reconcile medications and discontinue or reduce agents with no meaningful benefit or unacceptable toxicity.PubMedPubMedBest Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care

For PSP and CBS, prioritize falls prevention, transfer safety, gait and balance interventions, dysarthria and dysphagia assessment, and caregiver planning early because axial impairment, postural instability, bulbar dysfunction, and progressive functional dependency commonly drive morbidity.PubMed+1PubMedProgressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkersPubMedBest Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care Reassess swallowing and communication as symptoms evolve; the management consensus emphasizes regular identification of problems requiring treatment rather than waiting for a fixed diagnostic label.PubMed+1PubMedThe Differential Diagnosis and Treatment of Atypical ParkinsonismPubMedBest Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care

For MSA, address the autonomic syndrome in parallel with motor disability. Its characteristic combination of autonomic failure with variably expressed parkinsonism, cerebellar ataxia, and corticospinal features requires repeated review of orthostatic symptoms, urinary dysfunction, gait safety, and treatment adverse effects.PubMedPubMedA Guide for the Differential Diagnosis of Multiple System ... Diagnostic delays and misdiagnosis are common, so reconsider competing causes when the clinical pattern is discordant or treatment response is unexpected.PubMedPubMedA Guide for the Differential Diagnosis of Multiple System ...

For DLB-spectrum presentations, assess cognitive impairment, behavioral and neuropsychiatric symptoms, caregiver strain, and medication effects as core management targets rather than considering them secondary to motor severity.PubMed+1PubMedThe Differential Diagnosis and Treatment of Atypical ParkinsonismPubMedThe Spectrum of Cognitive Impairment in Atypical Parkinsonism Syndromes: A Comprehensive Review of Current Understanding and Research Cognitive and neuropsychiatric manifestations may occur early and can substantially affect patient and caregiver quality of life.PubMedPubMedThe Spectrum of Cognitive Impairment in Atypical Parkinsonism Syndromes: A Comprehensive Review of Current Understanding and Research

Document both the motor syndrome and the dominant nonmotor phenotype: for example, “progressive parkinsonism with severe autonomic failure, clinically most consistent with MSA” or “asymmetric cortical parkinsonism consistent with CBS.” This separates a useful clinical working diagnosis from a pathologic claim that may not be knowable during life.PubMed+2PubMedAtypical parkinsonian syndromes: a general neurologist’s perspectivePubMedProgressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkersPubMedBest Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care

Refer for subspecialty reassessment when there is rapid progression, mixed syndromic features, a young or familial presentation, abnormal imaging raising concern for inherited disease, or poor concordance between the presumed syndrome and observed course.Nature+2NatureRevisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases | npj Parkinson's DiseasePubMedAtypical parkinsonian syndromes: a general neurologist’s perspectivePubMedA Guide for the Differential Diagnosis of Multiple System ... Specialist evaluation is particularly valuable because early differentiation among Parkinson disease, DLB, MSA, PSP, and CBS can be difficult even with contemporary criteria.Nature+1NatureRevisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases | npj Parkinson's DiseasePubMedThe Differential Diagnosis and Treatment of Atypical Parkinsonism

Discuss research referral selectively when biomarker testing, genetics, or disease-specific trials could alter eligibility, while explaining that alpha-synuclein assays and other biomarkers remain under validation for diagnostic use.NatureNatureRevisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases | npj Parkinson's Disease Continue symptom-directed treatment and safety interventions irrespective of research participation.